Wire
UBS Adjusts Price Target on Children's Place to $3.50 From $4.50, Maintains Neutral Rating
UBS Adjusts Price Target on Children's Place to $3.50 From $4.50, Maintains Neutral Rating
$PLCE
$PLCE
3 stories mentioning PLCEUpdated 35d ago
Every FINWIRES story that references PLCE, newest first.
Wire
Top Midday Decliners
Replimune (REPL) is facing "significant risk" related to its ongoing phase 3 trial of RP1 in melanoma after the US Food and Drug Administration rejected the company's biologics license application for the product candidate, Wedbush Securities said in a note.Wedbush downgraded its rating on Replimune to neutral from outperform, with a lower price target of $2 from $19.Shares sank 64% following an increase in intraday trading volume to over 53.9 million from a daily average of about 1.84 million.Children's Place (PLCE) reported a fiscal Q4 adjusted loss and a decline in revenue from a year ago late Friday.Shares slumped 26% as intraday trading volume soared to more than 1.39 million from a daily average of about 276,000.Fastenal (FAST) reported Q1 earnings and sales Monday in line with the FactSet consensus.Its shares were down 7%, with intraday trading volume at more than 10.9 million, compared with the stock's daily average of about 8.68 million.Price: $1.69, Change: $-3.08, Percent Change: -64.60%
$FAST$PLCE$REPL
Wire
Children's Place Fiscal Q4 Adjusted Loss Widens, Revenue Falls; Shares Drop After Hours
Children's Place (PLCE) reported a fiscal Q4 adjusted loss late Friday of $1.86 per diluted share, widening from the loss of $0.75 a year earlier.One analyst polled by FactSet expected a loss of $0.96.Revenue in the three months ended Jan. 31 fell to $329.2 million from $408.6 million a year earlier.One analyst surveyed by FactSet expected $358.3 million.Children's Place shares fell 19% in after-hours trading.
$PLCE